Incyte Corporation (INCY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Incyte Corporation (INCY) has a cash flow conversion efficiency ratio of 0.080x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($507.66 Million) by net assets ($6.34 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Incyte Corporation for the company's overall valuation and market capitalisation.
Incyte Corporation - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Incyte Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Incyte Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Incyte Corporation ranked by their cash flow conversion efficiency. Explore INCY cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Dtech Technology Co. Ltd. A
SHE:301377
|
N/A |
|
Telefónica S.A
MX:TEFN
|
0.138x |
|
HEXAGON AB ADR/1
F:HXGC
|
0.071x |
|
Baidu Inc
MX:BIDUN
|
0.009x |
|
Zoom Video Communications Inc
NASDAQ:ZM
|
0.068x |
|
Dassault Aviation SA
PA:AM
|
0.191x |
|
Principal Financial Group Inc
NASDAQ:PFG
|
0.161x |
|
Alfa Laval AB
ST:ALFA
|
0.053x |
Annual Cash Flow Conversion Efficiency for Incyte Corporation (1993–2025)
The table below shows the annual cash flow conversion efficiency of Incyte Corporation from 1993 to 2025. View Incyte Corporation (INCY) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.15 Billion | $1.41 Billion | 0.274x | +181.93% |
| 2024-12-31 | $3.45 Billion | $335.34 Million | 0.097x | +1.67% |
| 2023-12-31 | $5.19 Billion | $496.49 Million | 0.096x | -56.90% |
| 2022-12-31 | $4.37 Billion | $969.94 Million | 0.222x | +11.64% |
| 2021-12-31 | $3.77 Billion | $749.49 Million | 0.199x | +516.64% |
| 2020-12-31 | $2.61 Billion | $-124.60 Million | -0.048x | -117.45% |
| 2019-12-31 | $2.60 Billion | $710.66 Million | 0.273x | +56.66% |
| 2018-12-31 | $1.93 Billion | $336.23 Million | 0.175x | +406.13% |
| 2017-12-31 | $1.63 Billion | $-92.99 Million | -0.057x | -107.85% |
| 2016-12-31 | $419.47 Million | $304.76 Million | 0.727x | +43.70% |
| 2015-12-31 | $171.16 Million | $86.54 Million | 0.506x | +192.50% |
| 2014-12-31 | $-48.04 Million | $26.26 Million | -0.547x | -1049.79% |
| 2013-12-31 | $-193.11 Million | $9.18 Million | -0.048x | -108.77% |
| 2012-12-31 | $-174.96 Million | $-94.83 Million | 0.542x | -23.89% |
| 2011-12-31 | $-227.08 Million | $-161.72 Million | 0.712x | +164.46% |
| 2010-12-31 | $-88.64 Million | $97.94 Million | -1.105x | -815.35% |
| 2009-12-31 | $-102.38 Million | $12.36 Million | -0.121x | -118.92% |
| 2008-12-31 | $-220.75 Million | $-140.86 Million | 0.638x | +9.81% |
| 2007-12-31 | $-159.52 Million | $-92.69 Million | 0.581x | -2.04% |
| 2006-12-31 | $-84.91 Million | $-50.37 Million | 0.593x | -88.71% |
| 2005-12-31 | $-19.40 Million | $-101.87 Million | 5.252x | +459.62% |
| 2004-12-31 | $78.52 Million | $-114.67 Million | -1.460x | -90.47% |
| 2003-12-31 | $154.33 Million | $-118.33 Million | -0.767x | -297.95% |
| 2002-12-31 | $302.41 Million | $-58.27 Million | -0.193x | -80.44% |
| 2001-12-31 | $440.20 Million | $-47.00 Million | -0.107x | -805.37% |
| 2000-12-31 | $622.69 Million | $-7.34 Million | -0.012x | +90.61% |
| 1999-12-31 | $170.30 Million | $-21.40 Million | -0.126x | -162.34% |
| 1998-12-31 | $179.60 Million | $36.20 Million | 0.202x | +50.58% |
| 1997-12-31 | $139.70 Million | $18.70 Million | 0.134x | -62.19% |
| 1996-12-31 | $45.20 Million | $16.00 Million | 0.354x | +284.07% |
| 1995-12-31 | $46.80 Million | $-9.00 Million | -0.192x | +26.74% |
| 1994-12-31 | $24.00 Million | $-6.30 Million | -0.263x | +3.95% |
| 1993-12-31 | $16.10 Million | $-4.40 Million | -0.273x | -- |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more